Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Rhythm Pharmaceuticals, Inc. (RYTM) reported a Q4 loss of $0.72 per share, slightly worse than the Zacks Consensus Estimate of a $0.69 loss. However, the company exceeded revenue expectations.
February 26, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Rhythm Pharmaceuticals reported a Q4 loss of $0.72 per share, missing the Zacks Consensus Estimate of $0.69. Despite the earnings miss, the company exceeded revenue expectations.
The earnings per share (EPS) was slightly worse than expected, which could negatively impact the stock price. However, the fact that revenue exceeded expectations may offset the negative impact of the EPS miss, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100